Author:
Jordan Berit,Zierz Stephan
Reference45 articles.
1. Aggarwal R, Charles-Schoeman C, Schessl J et al.: Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study) [abstract]. Arthritis Rheumatol (2020) 72
2. Birnkrant DJ, Bushby K, Bann CM et al.: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4) (2018) 347–361
3. Blaschek A, Vill K, Müller-Felber W, Schara U: Molecular therapies in childhood neuromuscular disorders-definite hope versus unknown pitfalls. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63(7) (2020) 891–897
4. Boentert M, Wenninger S, Sansone VA: Respiratory involvement in neuromuscular disorders. Curr Opin Neurol 30(5) (2017) 529–537
5. Bushby K, Finkel R, Wong B et al.: PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4) (2014) 477–487